← Leaderboards
Manjusha Gaglani
Scott And White Memorial Hospital
$20,161,078
Attributed
$20,161,078
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.4M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$20,161,078 · 4
By mechanism
U01$20,161,078 · 4
Top collaborators
No co-investigators on record.
Grant awards (23)
RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).$1,310,713
U01 · FY2025 · IP · contact PI
RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).$1,400,000
U01 · FY2024 · IP · contact PI
RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).$1,400,000
U01 · FY2023 · IP · contact PI
Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).$2,000,000
U01 · FY2022 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$1,800,000
U01 · FY2020 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$1,300,000
U01 · FY2019 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$700,000
U01 · FY2019 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$500,000
U01 · FY2019 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$500,000
U01 · FY2019 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$438,970
U01 · FY2019 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$1,300,000
U01 · FY2018 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$700,000
U01 · FY2018 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$800,000
U01 · FY2017 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$450,000
U01 · FY2017 · IP · contact PI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.$800,000
U01 · FY2016 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$419,098
U01 · FY2016 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$30,902
U01 · FY2016 · IP · contact PI
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness$801,316
U01 · FY2015 · IP · contact PI
Core_Apt Measure of PCR-based Influenza Vaccine Effectiveness in Inpatient Adults$300,000
U01 · FY2015 · IP · contact PI
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness$945,000
U01 · FY2014 · IP · contact PI
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness$785,000
U01 · FY2013 · IP · contact PI
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness$785,000
U01 · FY2012 · IP · contact PI
Core_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine Effectiveness$695,079
U01 · FY2011 · IP · contact PI